{"version":"1.0","type":"link","title":"First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison.","author_name":"Zhu Y 외","author_url":"https://prs-insight.online/author/Zhu%20Y","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/168089","thumbnail_width":1200,"thumbnail_height":630}